Brent Johnson Sells 3,000 Shares of Iradimed Corp (IRMD) Stock

Share on StockTwits

Iradimed Corp (NASDAQ:IRMD) VP Brent Johnson sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, May 17th. The shares were sold at an average price of $21.83, for a total transaction of $65,490.00. Following the transaction, the vice president now directly owns 4,368 shares of the company’s stock, valued at approximately $95,353.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Brent Johnson also recently made the following trade(s):

  • On Monday, May 20th, Brent Johnson sold 2,000 shares of Iradimed stock. The shares were sold at an average price of $22.53, for a total transaction of $45,060.00.
  • On Wednesday, March 13th, Brent Johnson sold 52,492 shares of Iradimed stock. The shares were sold at an average price of $24.42, for a total transaction of $1,281,854.64.
  • On Monday, March 11th, Brent Johnson sold 17,033 shares of Iradimed stock. The shares were sold at an average price of $25.38, for a total transaction of $432,297.54.
  • On Wednesday, March 6th, Brent Johnson sold 9,672 shares of Iradimed stock. The shares were sold at an average price of $24.58, for a total transaction of $237,737.76.

Shares of Iradimed stock opened at $22.36 on Thursday. Iradimed Corp has a 1 year low of $18.20 and a 1 year high of $38.78. The company has a market cap of $249.54 million, a price-to-earnings ratio of 52.00 and a beta of 1.70. The company has a debt-to-equity ratio of 0.06, a current ratio of 9.48 and a quick ratio of 8.63.

Iradimed (NASDAQ:IRMD) last announced its earnings results on Tuesday, April 30th. The medical equipment provider reported $0.11 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.11. Iradimed had a net margin of 23.00% and a return on equity of 13.98%. The business had revenue of $8.44 million during the quarter, compared to analyst estimates of $8.38 million. Equities research analysts predict that Iradimed Corp will post 0.64 earnings per share for the current fiscal year.

Several brokerages have issued reports on IRMD. BidaskClub lowered shares of Iradimed from a “buy” rating to a “hold” rating in a research report on Thursday, May 9th. Zacks Investment Research upgraded shares of Iradimed from a “hold” rating to a “buy” rating and set a $28.00 target price for the company in a research report on Tuesday, May 7th. Finally, ValuEngine lowered shares of Iradimed from a “buy” rating to a “hold” rating in a research report on Wednesday, May 1st. Two analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Iradimed currently has a consensus rating of “Buy” and an average price target of $31.50.

A number of institutional investors have recently made changes to their positions in the business. Renaissance Technologies LLC lifted its holdings in shares of Iradimed by 8.0% in the 1st quarter. Renaissance Technologies LLC now owns 346,200 shares of the medical equipment provider’s stock worth $9,725,000 after acquiring an additional 25,700 shares during the last quarter. BlackRock Inc. lifted its holdings in shares of Iradimed by 6.2% in the 1st quarter. BlackRock Inc. now owns 341,550 shares of the medical equipment provider’s stock worth $9,595,000 after acquiring an additional 19,930 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Iradimed by 19.7% in the 3rd quarter. Vanguard Group Inc. now owns 250,298 shares of the medical equipment provider’s stock worth $9,298,000 after acquiring an additional 41,184 shares during the last quarter. Vanguard Group Inc lifted its holdings in shares of Iradimed by 19.7% in the 3rd quarter. Vanguard Group Inc now owns 250,298 shares of the medical equipment provider’s stock worth $9,298,000 after acquiring an additional 41,184 shares during the last quarter. Finally, Ranger Investment Management L.P. lifted its holdings in shares of Iradimed by 13.3% in the 4th quarter. Ranger Investment Management L.P. now owns 190,226 shares of the medical equipment provider’s stock worth $4,653,000 after acquiring an additional 22,341 shares during the last quarter. Institutional investors and hedge funds own 23.01% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by Highlight Press and is the property of of Highlight Press. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://highlightpress.com/2019/05/23/brent-johnson-sells-3000-shares-of-iradimed-corp-irmd-stock.html.

Iradimed Company Profile

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system.

Featured Story: Understanding Compound Annual Growth Rate (CAGR)

Insider Buying and Selling by Quarter for Iradimed (NASDAQ:IRMD)

Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.